Long-term toxicity of chemotherapy for testicular cancer – the cost of cure
Open Access
- 1 March 1990
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 61 (3) , 479-484
- https://doi.org/10.1038/bjc.1990.106
Abstract
Twenty-seven patients cured of advanced testicular cancer by cisplatin-based chemotherapy have been assessed, a median of 30 months after start of treatment, for the long-term effects of such treatment on renal, endocrine, audiometric, reproductive and respiratory function. To control for the effects of orchidectomy on endocrine function a similar group of 11 patients cured by orchidectomy alone was also assessed. The extents of impairment in hearing and renal function were related to the total dose of cisplatin received, while the majority of patients had respiratory impairment which was, in part, related to the total dose of bleomycin. TSH was significantly higher in the chemotherapy group although serum free thyroxine and free T3 were normal in all. FSH was raised in 67% of the chemotherapy group although serum free thyroxine and free T3 were while LH was raised in 75% and 45% respectively. Serum testosterone was normal in all. The levels of FSH and LH were both independently correlated with age of the patient while FSH was higher in patients having more chemotherapy and had a tendency to fall towards normal with time since treatment. Over half the patients had normal sperm concentrations although 74% had a raised proportion of abnormal sperm. Indices of sperm function were worse in patients having more chemotherapy but sperm number increased towards normal with time since treatment, particularly after the second year. The long-term side-effects of chemotherapy for testicular cancer are thus generally mild but are largely irreversible and their severity is related to the total amount of chemotherapy received. As their longer term significance is not clear we would recommend that, in the treatment of testicular cancer, doses of chemotherapy are reduced to the minimum required for cure. Assessment of long-term side-effects of chemotherapy for testicular cancer should be a mandatory part of any study of such treatment and should be considered in any comparison of different therapies.Keywords
This publication has 30 references indexed in Scilit:
- Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-doseCancer Chemotherapy and Pharmacology, 1988
- Predicted values: how should we use them?Thorax, 1988
- Ototoxicity of low- and moderate-dose cisplatinCancer, 1985
- ROLE OF CARBON MONOXIDE DIFFUSING CAPACITY IN THE EARLY DETECTION OF MAJOR BLEOMYCIN-INDUCED PULMONARY TOXICITYAustralian and New Zealand Journal of Medicine, 1985
- Testicular function following combination chemotherapy with Cis‐platin, vinblastine, and bleomycinMedical and Pediatric Oncology, 1983
- Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratomaEuropean Journal of Cancer and Clinical Oncology, 1982
- TESTICULAR CANCER IN ENGLAND AND WALES: SOME EPIDEMIOLOGICAL ASPECTSThe Lancet, 1981
- Auditory toxicity effects of long‐term cis‐dichlorodiammineplatinum II therapy in genitourinary cancer patientsJournal of Surgical Oncology, 1981
- Serum Hormone Levels in Patients with Malignant Testicular Germ Cell Tumours without Clinical and/or Radiological Sings of TumourBritish Journal of Urology, 1980
- cis-Platinum OtotoxicityClinical Toxicology, 1978